The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1692
ISSUE 1692
December 25, 2023
Issue 1692
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Zuranolone (Zurzuvae) – An Oral Drug for Postpartum Depression
December 25, 2023 (Issue: 1692)
The FDA has approved the oral GABAA receptor
modulator zuranolone (Zurzuvae – Sage Therapeutics/Biogen) for treatment of postpartum depression
(PPD). Zuranolone is the second drug to be approved
for this indication; brexanolone (Zulresso),...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.